tetano
Editor, Senior Moderator
mBio
. 2024 Sep 20:e0130324.
doi: 10.1128/mbio.01303-24. Online ahead of print. SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study
Urban Hellman[SUP] 1 2 [/SUP], Ebba Rosendal[SUP] 1 3 [/SUP], Joakim Lehrstrand[SUP] 4 [/SUP], Johan Henriksson[SUP] 3 5 6 [/SUP], Tove Björsell[SUP] 7 [/SUP], Alfred Wennemo[SUP] 1 [/SUP], Max Hahn[SUP] 4 [/SUP], Björn Österberg[SUP] 8 [/SUP], Luiza Dorofte[SUP] 9 [/SUP], Emma Nilsson[SUP] 1 3 [/SUP], Mattias N E Forsell[SUP] 1 [/SUP], Anna Smed-Sörensen[SUP] 8 [/SUP], Anna Lange[SUP] 10 [/SUP], Mats G Karlsson[SUP] 9 [/SUP], Clas Ahlm[SUP] 1 [/SUP], Anders Blomberg[SUP] 2 [/SUP], Sara Cajander[SUP] 10 [/SUP], Ulf Ahlgren[SUP] 4 [/SUP], Alicia Lind[SUP] 11 [/SUP], Johan Normark[SUP] 1 12 [/SUP], Anna K Överby[SUP] #[/SUP][SUP] 1 3 [/SUP], Annasara Lenman[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS, 6-9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.IMPORTANCEThis study provides insights into the role of hyaluronan (HA) in the severity and long-term impact of COVID-19 on lung function. Through extensive morphological examination of lung tissues and a multicenter study, we identified that HA levels are significantly elevated in COVID-19 patients, correlating with a reduced lung diffusion capacity during convalescence. Using a 3D-lung model, we further uncovered how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection causes a dysregulated HA metabolism, leading to increased HA production. Our findings provide valuable insights into the pathogenesis of SARS-CoV-2 and suggest that targeting HA metabolism could offer new therapeutic avenues for managing COVID-19, particularly to prevent long-term lung impairment. Additionally, HA holds potential as a biomarker for predicting disease severity, which could guide personalized treatment strategies.
Keywords: 3D-lung model; COVID-19; SARS-CoV-2; hyaluronan; hyaluronic acid; lung impairment.
. 2024 Sep 20:e0130324.
doi: 10.1128/mbio.01303-24. Online ahead of print. SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study
Urban Hellman[SUP] 1 2 [/SUP], Ebba Rosendal[SUP] 1 3 [/SUP], Joakim Lehrstrand[SUP] 4 [/SUP], Johan Henriksson[SUP] 3 5 6 [/SUP], Tove Björsell[SUP] 7 [/SUP], Alfred Wennemo[SUP] 1 [/SUP], Max Hahn[SUP] 4 [/SUP], Björn Österberg[SUP] 8 [/SUP], Luiza Dorofte[SUP] 9 [/SUP], Emma Nilsson[SUP] 1 3 [/SUP], Mattias N E Forsell[SUP] 1 [/SUP], Anna Smed-Sörensen[SUP] 8 [/SUP], Anna Lange[SUP] 10 [/SUP], Mats G Karlsson[SUP] 9 [/SUP], Clas Ahlm[SUP] 1 [/SUP], Anders Blomberg[SUP] 2 [/SUP], Sara Cajander[SUP] 10 [/SUP], Ulf Ahlgren[SUP] 4 [/SUP], Alicia Lind[SUP] 11 [/SUP], Johan Normark[SUP] 1 12 [/SUP], Anna K Överby[SUP] #[/SUP][SUP] 1 3 [/SUP], Annasara Lenman[SUP] #[/SUP][SUP] 1 [/SUP]
Affiliations
- PMID: 39302125
- DOI: 10.1128/mbio.01303-24
We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS, 6-9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity. In vitro 3D-lung models, differentiated from primary human bronchial epithelial cells, were used to study the effects of SARS-CoV-2 infection on HA metabolism, and transcriptomic analyses revealed a dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Furthermore, corticosteroid treatment reduced the inflammation and downregulated HA synthases. Our findings demonstrate that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment.IMPORTANCEThis study provides insights into the role of hyaluronan (HA) in the severity and long-term impact of COVID-19 on lung function. Through extensive morphological examination of lung tissues and a multicenter study, we identified that HA levels are significantly elevated in COVID-19 patients, correlating with a reduced lung diffusion capacity during convalescence. Using a 3D-lung model, we further uncovered how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection causes a dysregulated HA metabolism, leading to increased HA production. Our findings provide valuable insights into the pathogenesis of SARS-CoV-2 and suggest that targeting HA metabolism could offer new therapeutic avenues for managing COVID-19, particularly to prevent long-term lung impairment. Additionally, HA holds potential as a biomarker for predicting disease severity, which could guide personalized treatment strategies.
Keywords: 3D-lung model; COVID-19; SARS-CoV-2; hyaluronan; hyaluronic acid; lung impairment.